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Summary
Objective: To test the hypothesis that early knee and hand osteoarthritis (OA) development is characterized by detectable changes in serum
proteins relevant to inﬂammation, cell growth, activation, and metabolism several years before OA becomes radiographically evident.
Methods: Using microarray platforms that simultaneously test 169 proteins relevant to inﬂammation, cell growth, activation and metabolism,
we conducted a caseecontrol study nested within the Baltimore Longitudinal Study of Aging (BLSA). Subjects included 22 incident cases of
OA and 66 age-, sex- and body mass index (BMI)-matched controls. Serum samples tested were obtained at the time of radiographic
classiﬁcation as either case or control, and up to 10 years earlier at a time when all participants were free of radiographic OA. Proteins
with mean signal intensities fourfold higher than background were compared between cases and controls using multivariate techniques.
Results: Sixteen proteins were different between OA cases compared to controls. Four of these proteins [matrix metalloproteinase (MMP)-7,
interleukin (IL)-15, plasminogen activator inhibitor (PAI)-1 and soluble vascular adhesion protein (sVAP)-1] were already different in samples
obtained 10 years before radiographic classiﬁcation and remained different at the time of diagnosis. Six additional proteins were only
associated with subsequent OA development and not with established OA.
Conclusions: Changes in serum proteins implicated in matrix degradation, cell activation, inﬂammation and bone collagen degradation
products accompany early OA development and can precede radiographic detection by several years.
Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
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Osteoarthritis (OA)1 is a highly prevalent chronic health
condition that causes substantial disability in late life. At
present, conventional radiography is considered the gold
standard for the diagnosis of OA but cannot detect early
disease or subtle changes over time. To overcome these
limitations, the search for diagnostic and prognostic
biomarkers has intensiﬁed over recent years. Early studies
focusing on cartilage precursors, constituents and degrada-
tion products2e4 suggest that perturbation of the delicate
balance between degradation and repair mechanisms
which eventually lead to cartilage degeneration e occur in*Address correspondence and reprint requests to: Dr Shari
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43the early stages of OA development2,5. Additional studies
aimed at identifying imaging markers of OA have demon-
strated that OA pathogenesis involves other tissues includ-
ing bone, synovium and meniscus6. Additional evidence is
mounting to suggest that clusters of markers7e9 may com-
prise ‘‘signatures’’ predictive of OA development, activity
or progression. Reliable and valid biomarkers may identify
individuals at high risk of OA9e11 who may be ideal partici-
pants for clinical trials testing interventions of disease
modiﬁcation12,13.
One promising approach to identify biomarkers that can re-
veal the early stages of OA development is to apply high sen-
sitivity technology to characterize the proﬁle of candidate
circulating proteins in subjects who have been radiographi-
cally characterized atmultiple points in time overmany years.
Following this line of investigation, we conducted a casee
control study nested within the Baltimore Longitudinal Study
of Aging (BLSA) to test the hypothesis that the early stage of
knee and hand OA development is characterized by detect-
able changes in serum proteins relevant to inﬂammation,
44 S. M. Ling et al.: Serum protein signatures of OAcell growth, activation, and metabolism several years before
OA becomes radiographically evident.
MethodsDESIGNWe conducted a caseecontrol study nested within the BLSA. The BLSA is
a longitudinal normative aging study where a cohort of volunteers has been
followed prospectively through comprehensive biennial examinations for
more than 40 years14. The BLSA is conducted by the National Institute on
Aging intramural research scientists of the Clinical Research Branch,
presently located at Harbor Hospital, Baltimore, Maryland. This study was
approved by the Institutional Review Board of the MedStar Research Insti-
tute (MRI 2003-076).PARTICIPANTSParticipants were community-dwelling healthy volunteers 19e92 years
old at study entry, mostly of Caucasian race (96%) and upper middle-class
socioeconomic status.SELECTION OF CASES AND CONTROLSSingle posteroanterior radiographs of both hands and weight-bearing,
fully extended anteroposterior radiographs of both knees were obtained at
one or more visits between 1984 and 1991 and a repeat set of knee X-
rays was obtained using the same methodology between 1995 and 1998
as previously reported15. The mean interval between the initial and follow-
up X-rays was approximately 10 years (range 9.3e11.9 years) and did not
differ between cases and controls.
All radiographs obtained at both time points were independently evalu-
ated for OA using the KellgreneLawrence (KL) grades as described in the
Atlas of Standard Radiographs16. Deﬁnite OA of the knee was deﬁned as
KL grade 2 or higher of either knee. Hand OA was deﬁned as a KL grade
of 2 or higher at one or more of the ﬁrst carpalemetacarpal, second or third
distal or proximal interphalangeal joints of either hand. Paired radiographs
were read by two trained readers blinded from the participant’s identity,
time and sequence of examination; a third trained reader adjudicated
disagreements. The intra-class correlation coefﬁcient for agreement on KL
grade between the two reviewers was previously published as 0.83e0.85
for baseline and follow-up ﬁlms17.
BLSAparticipants were eligible for this study if they had two sets of X-rayse
the ﬁrst of which had been scored as no evidence of OA, and a set of banked
serum samples obtained over the corresponding time interval. Participants
who had radiographic OA of one or both knees and one or both hands on
the second X-ray were classiﬁed as ‘‘incident OA’’ cases. Controls were par-
ticipants with normal X-rays at both time points selected to match OA cases
by age-decade, sex and body mass index (BMI) category. Serum samples
identiﬁed for testing were obtained during the initial X-ray visit and a second
sample obtained on average 10 years later during the classifying X-ray visit.
Rolling Circle Amplification (RCA) Assays: Serum samples were obtained
after an overnight fast, immediately processed, and stored at 80C until
testing. RCA enhanced antibody-based protein microarrays were used to
assay samples for 169 proteins that spanned cytokines, chemokines, growth
factors, apoptosis regulators, soluble receptors, adhesion molecules,
enzymes, proteases and their inhibitors, coagulation factors, cell cycle
proteins and hormones. Samples were thawed, centrifuged to remove partic-
ulate matter and mixed with 0.25-mg/ml Heteroblock (Omega), 0.25-mg/ml
immunoglobulin inhibiting reagent (Bioreclamation) and 0.1% Tween-20 prior
to the assay. Twenty microliters of the treated sample were then applied to
each sub-array. As described in detail by others18,19, measurements are
performed when the sample protein is captured by speciﬁc antibody afﬁxed
to the chipA secondary detector antibody binds to the captured protein, and
is bound by a universal antibody afﬁxed with RCA signal ampliﬁer. Each
analyte was tested in quadruplicate. Four quality controls with known con-
centrations corresponding to four anchor points on the full titration curve
were included on each sample slide. The slides were scanned using
a LS200 scanner (TECAN) and analyzed using proprietary software
(Molecular Staging, Inc). The ﬂuorescence intensity of microarray spots
was analyzed for each analyte and the resulting mean intensity values
were determined. Standard curves for selected proteins were examined to
ensure that increasing intensity corresponded to increasing analyte concen-
tration. Slide-to-slide precision was improved using regression-based nor-
malization (normalization method based on analytically identifying and
excluding random background noise) with coefﬁcients of variation of 17%,
20%, 17%, 19%, 18%, and 17%.DATA ANALYSISAll analyses were performed on samples with mean ﬂuorescence intensity
at least fourfold greater than background, using normalized z-scoresseparately. Non-normally distributed data were log-transformed prior to anal-
ysis. Data were analyzed using mixed model analysis of variance (ANOVA)
and signiﬁcant analysis of microarray (SAM)20 e a statistical technique that
can be used to correlate protein expression data to a wide range of param-
eters by repeated measurement. This analytic technique was applied to iden-
tify signiﬁcant proteins that distinguish OA from control samples. In the
ANOVA analysis, individual samples were treated as the random effect, visit
time as repeated measures, and ‘‘OA’’ vs ‘‘no OA’’ as a ﬁxed effect. In the
SAM analysis, proteins with different concentrations were determined based
on the false discovery rate via permutations. The potential to discriminate OA
cases and controls based on aggregated measures of proteins with different
concentrations was further examined by principal component analysis
(PCA). Finally, we used decision tree analyses to assess classiﬁcation accu-
racy between OA and controls based on the proteins with different concen-
trations. We constructed a binary response tree using assignment as a case
or control to recursively partition the data into one of two non-empty groups.
This is repeated until the terminal nodes are too small or too few to be split
further21. The differentially expressed proteins were examined by neural net-
work classiﬁcation using a process of ‘supervised learning’. The entire pro-
tein microarray data set was randomly divided into two parts. The ﬁrst part,
which consisted of total 70% of the data source, was used as the training
data set. The remaining 30% of data was used to verify the accuracy of
the classiﬁcation as a case or control. Predicted results were pooled together
into receiver operator characteristic (ROC) curves to assess sensitivity and
speciﬁcity of the differentially expressed proteins for discriminating OA cases
from controls, and compared to ROC curves based on all assessed proteins.
Finally, mixed effects modeling repeated measure ANOVA was applied to
explore age-associated differences between three age groups: <44 years
(n¼ 40), 45e69 (n¼ 91) and 70þ years (n¼ 38).
All analyses were performed using the commercial software Partek and
Insightful Miner 3.0 and the open source R package Bioconductor.Results
We analyzed serum samples from 22 participants classi-
ﬁed as incident knee OA and 66 controls who remained OA
free over the entire study period. Testing yielded data of
acceptable quality for all participants at the initial X-ray visit,
and all but two cases at the classifying X-ray visit. The time
between X-rays did not differ between cases and controls
(mean S.E.M. 10.03 0.31 years for OA and 9.88 0.22
years for controls; P> 0.05). The initial ages of participants
ranged from 22 to 92 years. Hand OA was present in nine of
the 21 knee OA participants at the time of the initial X-ray
visit, and 10 of the 19 participants at the time of classifying
X-ray visit but was not present in controls. The number of
participants represented in these analyses stratiﬁed by
age group is reported in Table I. Overall, 16 proteins were
signiﬁcantly different between cases and controls at the
time of classiﬁcation. The protein signatures predictive of
OA development compared to those individuals remaining
OA free include 10 proteins that were different at the initial
X-ray visit [Fig. 1(A)]. Most of these proteins were observed
in lower concentrations (negative z-scores) in OA samples
with few exceptions. Furthermore, the differences between
OA cases and controls appear more dramatic in the youn-
ger age groups. Similarly, Fig. 1(B) depicts the protein con-
centration patterns detected in blood samples collected at
the time of the second X-ray. Comparison of the two
patterns demonstrates consistency between the signature
predictive of OA development and that associated with
OA presence. Table II lists the fold changes of these protein
signatures distinguish OA from control samples for all ages
at the time of initial and classifying X-rays. The fold change
was calculated by dividing the averaged value of OA cases
by the averaged value of controls. If this number was less
than one the (negative) reciprocal is listed.
The results of the PCAs are consistent with the ﬁndings
reported above. Figure 1(C) illustrates results of PCA that
uses proteins that were different at the time of the initial
X-ray. The three principal components (PCs) accounted
for 57.4% total variability (38.8%, 9.7% and 8.9% for the
Fig. 1. Protein signatures distinguish OA from control samples at both time points. The differences in protein expression between cases and
controls at the initial X-ray visit (panel A) and at the classifying X-ray visit (panel B) are displayed in the heat-maps. Red depicts proteins that
are expressed at higher concentrations in OA samples, while green indicates protein expression at lower concentrations in OA samples. Black
spots indicate proteins that were not different between OA and control samples. In both heat-maps, samples are horizontally grouped accord-
ing to the classiﬁcation of OA and controls, and by age group. Vertically the proteins are arranged by unweighted pair group method with
arithmetic mean (UPGMA) clustering based on the z-score expression values. The differentially expressed proteins analyzed by PCA are plot-
ted separately with the X, Y and Z axes signifying the ﬁrst, second and third PCs with OA-associated proteins are represented in blue and
control-associated proteins in red. The 10 differentially expressed proteins predictive of OA development at the initial X-ray visit (panel C)
and the 16 proteins associated with OA at the classifying X-ray visit (panel D) illustrate separation of cases from controls at both time points.
45Osteoarthritis and Cartilage Vol. 17, No. 1ﬁrst, second and the third PCs, respectively). The discrimi-
nation between cases and controls using the 16 proteins
differentially expressed at X-ray classiﬁcation is illustrated
in Fig. 1(D). Three PCs accounted for 56.5% of the total
variability (26.3%, 17.9% and 12.3% for the main three
components). When a similar PCA was conducted using
all 169 proteins, the discrimination between cases and con-
trols was signiﬁcantly lower and accounted for only 37.0%Table
Characteristics of BLSA participants represented
Initial X-ray (1984e1991)
OA (n¼ 21) Controls






BMI (kg/m2) 25.4 3.07 25.6 4.of total variability (18.8%, 9.9%, and 8.3% for the main three
components) at the ﬁrst time point and 34.1% of total vari-
ability (14.8%, 10.9%, and 8.4% for the main three
components) at the second time point (data not shown).
The ROC characteristics of the 10 differentially expressed
OA-predictive proteins and the 16 differentially expressed
OA-associated proteins were superior to all 169 proteins
in discriminating cases from controls (data not shown).I
at the time of initial and classifying X-rays
Classifying X-ray (1994e1996)
(n¼ 61) OA (n¼ 19) Controls (n¼ 66)





4 26.7 4.8 26.9 4.8
46 S. M. Ling et al.: Serum protein signatures of OAProteins evaluated at the initial X-ray that predicted OA
development included increased matrix metalloproteinase
(MMP)-7, soluble vascular adhesion protein (sVAP)-1and
interleukin (IL)-15, and decreased MMP-2, plasminogen ac-
tivator inhibitor (PAI)-1, D-dimers (DD)5 and DD6, eotaxin-2
(Eot-2), intracellular adhesion molecule (ICAM-1), and P-
selectin. Proteins that were different between OA and
controls at the time of the classifying X-ray included higher
concentrations of proteins relevant to immune response
and inﬂammation e B-lymphocyte chemokine (BLC), 6-che-
mokine (6Ckine), macrophage inhibitory protein (MIP)-1a,
IL-1a, IL-2, IL-15, MMP-7; growth and repair e ﬁbroblast
growth factor (FGF)-7, insulin-like growth factor (IGF) bind-
ing protein-2, granulocyte macrophage colony stimulating
factor (GM-CSF), neurotrophin-4 (NT-4); and cellular and
vascular adhesion matrix integrity e ICAM-3, vascular ad-
hesion protein-1 (VAP-1), and vascular endothelial (VE)-
cadherin. Four of these proteins, IL-15, MMP-7, VAP-1
and PAI-1, were different between cases and controls at
both time points with IL-15, MMP-7 and VAP-1 increased
and PAI-I decreased in OA cases relative to controls. Al-
though we also examined these OA-predictive and OA-as-
sociated proteins for age effects, only MMP-7 expression
was also differentially expressed at higher concentrations
in the 45e69 and 70þ year compared to the <44-year-old
samples (data not shown; P< 0.05).
Finally, using recursive partitioning21, we explored the
relationships between individual proteins with different
concentrations, and their ability to discriminate cases from
controls using z-score thresholds at the initial [Fig. 2(A)]
and classifying [Fig. 2(B)] X-ray visits. These ﬁgures illus-
trate the discriminative value of a given protein in classifying
participants as cases or controls is inﬂuenced by the
concentration of other proteins (e.g., ICAM-1) and also
differed between visits (e.g., PAI-1). The misclassiﬁcation
error rate was 0.061 for the 10 OA-predictive proteins
observed at the initial X-ray visit, and 0.071 for the 16
OA-associated proteins observed at the classifying X-ray
visit [Fig. 2(B)].Fig. 2. Classiﬁcation tree using proteins that were different at initial and
classifying X-ray visits. Recursive regression tree classiﬁcation of OA
cases and control samples based on protein amount observed at the
time of the initial X-ray (A), and at the time of the classifying X-ray (B). Be-
side each protein appears the threshold z-score used to classify samples.
The odds ratios associated with each protein appear in the brackets. Two
numbers are displayed on each node (depicted as circle for non-terminal
nodes or square for terminal nodes): the number of samples classiﬁed as
OAby that protein is shownon the topand thenumber of participants clas-
siﬁed as controls is shown on the bottom. The misclassiﬁcation error rate
was 0.061 for (A), and 0.071 for (B).Discussion
This is the ﬁrst study to demonstrate serum protein signa-
tures associated with OA. Using a caseecontrol design
nested in a large longitudinal study of normative aging,
we detected 16 proteins that were different in participants
with radiographic knee and hand OA compared to age-,
gender-, and BMI-matched controls free of OA. Four of
these proteins (MMP-7, IL-15, PAI-1 and sVAP-1) associ-
ated with OA presence at the time of the classifying X-ray
were also differentially expressed between cases and
controls, at a time when OA was not detectable by conven-
tional X-ray. Six additional proteins were different between
OA cases and controls at a time when radiographic
evidence of OA was not present, but not 10 years later
when radiographic features had developed. We have also
clearly demonstrated that these signatures more accurately
distinguished cases from controls at both time points than
all proteins assayed, and that there is overlap and consis-
tency in the protein signatures associated with OA at the
two points in time.
It is plausible that the protein signatures identiﬁed in
association with OA are serum markers of disease initiating
events (initial OA signature) or disease sustaining events
(prevalent OA signature). Accordingly, our data suggest
that altered extracellular matrix metabolism plays a centralrole in OA initiation. The pattern includes a shift away
from constitutively expressed MMP-2 toward higher MMP-7
expression and propensity for enhanced plasmin activation
to render extracellular matrix vulnerable to degeneration
and injury is consistent with previous reports of MMP-7
over expression in human OA chondrocytes22 and synovial
ﬂuid samples23, and may also explain the lower PAI-1 con-
centrations observed in OA samples that has not previously
Table II
Fold changes of protein signatures distinguish OA from control
samples at the time of initial and classifying X-rays
Initial X-ray (1984e1991) Classifying X-ray (1994e1996)
Protein Fold change Proteins Fold change
IL-15 1.242 IL-15 1.182
MMP-7 1.298 MMP-7 1.239
PAI-1 1.111 PAI-1 1.132
VAP-1 1.133 VAP-1 1.228
DD5 1.184 6Ckine 1.167
DD6 1.30 BLC 1.207
Eot-2 1.503 FGF-7 1.188
ICAM-1 1.492 GM-CSF 1.165
MMP-2 1.122 ICAM-3 1.191







47Osteoarthritis and Cartilage Vol. 17, No. 1been reported. The observations of higher IL-15, VAP-1 and
adhesion molecule concentrations in OA samples, although
not previously reported, suggest that cellular and immune
mechanisms contribute to OA initiation. The sustained pro-
ﬁle comprised of high MMP-7, IL-15, VAP and low PAI-1 as-
sociated with prevalent OA suggest that these same
mechanisms also contribute to OA perpetuation. However,
in contrast to the earlier time point, the protein signature as-
sociated with prevalent OA suggests that reparative mech-
anisms are operative, as evidenced by over-expressed
tissue inhibitor of metalloproteinases (TIMPs) and growth
factors (FGF, IGF binding protein, GM-CSF, NT-4). The in-
creased expression of inﬂammatory cytokines and chemo-
kines associated with prevalent OA lend additional
support of the notion of OA as an inﬂammatory disease.
The protein signatures associated with OA in this study
are not speciﬁc to cartilage, and therefore understandably
distinct from those identiﬁed in microarray studies of carti-
lage24. These proteins cannot be presumed to cartilage-
speciﬁc events although collagen turnover products are
also associated with OA in our study. Interestingly, some
of the proteins identiﬁed that were associated with older
age (e.g., IL-6) are also associated with frailty and sarcope-
nia. With rare exceptions, the proteins associated with OA
were distinct from the expression pattern associated with
and predictive of OA development.
Although these results advance our understanding of the
molecular markers of OA, there are several limitations
inherent in the data. First, this study is based upon microar-
ray data and hence vulnerable to the criticisms implicit to
this technology. The simultaneous quantiﬁcation of 169 pro-
teins might be regarded as ‘‘ﬁshing.’’ However the speciﬁc
proteins selected a priori for this chip include mediators of
inﬂammation, cell growth, activation and metabolism that
are relevant to OA pathogenesis. Additionally, a number
of quality control features such as target speciﬁcity and
use of a four-fold change as the threshold for inclusion
were implemented to reduce the chance of false positive
results. Despite the considerable improvement, the sensitiv-
ity of this RCA-based assay remains inferior to conventional
enzyme-linked immunosorbent assays. We also acknowl-
edge the possibility that the length of storage prior to testing
may have compromised sample integrity. Therefore, wecannot exclude that some proteins important to the patho-
genesis of OA but with levels below the RCA limits of detec-
tion could not be identiﬁed. Second, the study sample is
small due to our adherence to very strict inclusion and ex-
clusion criteria with careful matching of controls to cases
on the most likely confounders of age group, sex and
BMI. While this approach increased the precision of our
measures and reduced the chances of outcome misclassi-
ﬁcation, the presence of a few outliers may have inﬂuenced
the analysis results. Due to the small sample size, we were
not able to examine signatures according to speciﬁc OA
sub-type or clinical pattern. Given the selection criteria for
this study, the OA-associated protein signatures identiﬁed
in this study are most relevant to OA of the knee that and
might be less relevant to OA of other locations, or that de-
velops secondary to other processes. Third, this study re-
lied on radiographic deﬁnitions of OA to classify
individuals as cases or controls. Given the limited sensitivity
of conventional X-rays for early changes of OA, it remains
possible that participants classiﬁed as ‘‘normal’’ may have
been affected by early OA that escaped radiographic
detection.
Despite the above limitations, this study offers new insight
that can be best gleaned through a prospective, long lasting,
longitudinal study such as the BLSA. We conclude that OA
of the knee and hand is associated with serum protein signa-
tures that include mediators of cellular activation, inﬂamma-
tion and matrix degradation, and that some of these proteins
were predictive of OA development years prior to radio-
graphic detection. Additionally, except for four proteins, the
set of proteins associated with OA at the time of the initial
X-ray was not different at the time of the second X-ray and
vice versa. These ﬁndings support the notion that these
protein signatures are responsive to change over time e
and that initiating events and their mediators are distinct
from those that sustain the disease. However, additional
studies are necessary to establish the utility of these protein
proﬁles for the diagnosis and monitoring of OA. The protein
signatures identiﬁed in this study may have utility as targets
of future intervention studies and/or as prognostic indicators
or predictors of therapeutic response.Conﬂict of interest
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